CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 11

Some of the metrics are blocked by your
consent settings
Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative
(Elsevier BV, 2025-06)
Juan I. Rojas
;
Liliana Patrucco
;
Edgardo Cristiano
;
José I. Gortari
;
Paola A. Ortiz Salas
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice
(2023)
Alex Aren
;
María José Moreta
;
Ingrid Ordás
;
Agnès Fernández-Clotet
;
Berta Caballol
1Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients
(2023)
POLI HARLOWE, MARIA CECILIA BERTA
;
VIAL COX, MARIA CECILIA
;
REY JURADO, EMMA
;
Natalia González
;
CORTES SALINAS, LINA JIMENA
<jats:p>Chronic kidney disease (CKD) patients have an increased risk of morbidity and mortality following SARS-CoV-2 infection. Vaccination in these patients is prioritized, and monitoring of the immune response is paramount to define further vaccination strategies. This prospective study included a cohort of 100 adult CKD patients: 48 with kidney transplant (KT) and 52 on hemodialysis without prior COVID-19. The patients were assessed for humoral and cellular immune responses after four months of an anti-SARS-CoV-2 primary two-dose vaccination scheme (CoronaVac or BNT162b2) and one month after a booster third dose of BNT162b2 vaccine. We identified poor cellular and humoral immune responses in the CKD patients after a primary vaccination scheme, and these responses were improved by a booster. Robust polyfunctional CD4+ T cell responses were observed in the KT patients after a booster, and this could be attributed to a higher proportion of the patients having been vaccinated with homologous BNT162b2 schemes. However, even after the booster, the KT patients exhibited lower neutralizing antibodies, attributable to specific immunosuppressive treatments. Four patients suffered severe COVID-19 despite three-dose vaccination, and all had low polyfunctional T-cell responses, underscoring the importance of this functional subset in viral protection. In conclusion, a booster dose of SARS-CoV-2 mRNA vaccine in CKD patients improves the impaired humoral and cellular immune responses observed after a primary vaccination scheme.</jats:p>
8Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease
(2020)
IBAÑEZ, SEBASTIAN
;
María Paz Poblete De La Fuente
;
Elisa Catalina Parra Cancino
3 1Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors
(2022)
Edgar Carnero Contentti
;
Pablo A López
;
Juan Criniti
;
Ricardo Alonso
;
Berenice Silva
<jats:sec><jats:title>Background:</jats:title><jats:p> Neuromyelitis optica spectrum disorder (NMOSD) misdiagnosis (i.e. the incorrect diagnosis of patients who truly have NMOSD) remains an issue in clinical practice. We determined the frequency and factors associated with NMOSD misdiagnosis in patients evaluated in a cohort from Latin America. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We retrospectively reviewed the medical records of patients with NMOSD, according to the 2015 diagnostic criteria, from referral clinics in six Latin American countries (Argentina, Chile, Paraguay, Colombia, Ecuador, and Venezuela). Diagnoses prior to NMOSD and ultimate diagnoses, demographic, clinical and paraclinical data, and treatment schemes were evaluated. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 469 patients presented with an established diagnosis of NMOSD (73.2% seropositive) and after evaluation, we determined that 56 (12%) patients had been initially misdiagnosed with a disease other than NMOSD. The most frequent alternative diagnoses were multiple sclerosis (MS; 66.1%), clinically isolated syndrome (17.9%), and cerebrovascular disease (3.6%). NMOSD misdiagnosis was determined by MS/NMOSD specialists in 33.9% of cases. An atypical MS syndrome was found in 86% of misdiagnosed patients, 50% had NMOSD red flags in brain and/or spinal magnetic resonance imaging (MRI), and 71.5% were prescribed disease-modifying drugs. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> NMOSD misdiagnosis is relatively frequent in Latin America (12%). Misapplication and misinterpretation of clinical and neuroradiological findings are relevant factors associated with misdiagnosis. </jats:p></jats:sec>
11Scopus© Citations 14
Some of the metrics are blocked by your
consent settings
Current knowledge of immunosuppression as a risk factor for skin cancer development
(2022)
ROLLAN MARZOLO, MARIA PAZ
;
CABRERA MORAGA, RAUL ALEJANDRO
;
Robert A. Schwartz
Scopus© Citations 18 5
Some of the metrics are blocked by your
consent settings
Diagnosis and classification of optic neuritis
(2022)
Axel Petzold
;
Clare L Fraser
;
Mathias Abegg
;
Raed Alroughani
;
Daniah Alshowaeir
Scopus© Citations 81 2
Some of the metrics are blocked by your
consent settings
Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis
(2020)
Gwen E. Thompson
;
Lynn A. Fussner
;
Amber M. Hummel
;
Darrell R. Schroeder
;
Francisco Silva
14Scopus© Citations 19
Some of the metrics are blocked by your
consent settings
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
(2020)
Rodrigo A. Valenzuela
;
Iván Flores
;
Beatriz Urrutia
;
Francisca Fuentes
;
Pablo E. Sabat
Scopus© Citations 28 2
Some of the metrics are blocked by your
consent settings
Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort
(2019)
V R Pimentel-Quiroz
;
M F Ugarte-Gil
;
GB Harvey
;
D Wojdyla
;
G J Pons-Estel
<jats:sec><jats:title>Aim</jats:title><jats:p> The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20–37) years and 47.8 (17.9–68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48–0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69–10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35–16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10–2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01–1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11–1.34; p < 0.0001) were predictive factors of serious infections. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients. </jats:p></jats:sec>
6Scopus© Citations 75

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results